Geng Shaohui, Hu Bohan, Guan Yiwei, Jiang Yijin, Shu Zixuan, Li Chen, Huang Guangrui
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
School of Chinese Materia Medica , Beijing University of Chinese Medicine, Beijing, China.
Front Immunol. 2024 Nov 26;15:1492878. doi: 10.3389/fimmu.2024.1492878. eCollection 2024.
The complex interaction between the immune system and autoinflammatory disorders highlights the centrality of autoimmune mechanisms in the pathogenesis of autoinflammatory diseases. With the exploration of PSTPIP2, it has been discovered to play an inhibitory role in immune diseases, suggesting its potential utility in the research and treatment of rheumatic diseases. This review outlines the mechanisms of PSTPIP2 in chronic multifocal osteomyelitis (CMO), rheumatoid arthritis (RA), synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, liver diseases, renal diseases, pressure ulcer sepsis and diabetic obesity. The mechanisms include inhibiting the IL-1β inflammatory responses, NF-κB, ERK phosphorylation etc., promoting Erβ, and modulating the polarization of macrophage to prevent the inflammatory diseases. This review summarized current findings and offered perspectives on future research directions, laying a foundation for applying of PSTPIP2 in inflammatory diseases.
免疫系统与自身炎症性疾病之间的复杂相互作用凸显了自身免疫机制在自身炎症性疾病发病机制中的核心地位。随着对PSTPIP2的探索,发现它在免疫疾病中发挥抑制作用,这表明其在风湿性疾病研究和治疗中的潜在用途。本综述概述了PSTPIP2在慢性多灶性骨髓炎(CMO)、类风湿关节炎(RA)、滑膜炎-痤疮-脓疱病-骨肥厚-骨炎(SAPHO)综合征、肝脏疾病、肾脏疾病、压疮败血症和糖尿病肥胖症中的作用机制。这些机制包括抑制IL-1β炎症反应、NF-κB、ERK磷酸化等,促进Erβ,并调节巨噬细胞极化以预防炎症性疾病。本综述总结了当前的研究结果,并对未来的研究方向提出了展望,为PSTPIP2在炎症性疾病中的应用奠定了基础。